Erratum: Ursodeoxycholic acid inhibits interleukin beta I and deoxycholic acid-induced activation of NF-κB and AP-1 in human colon cancer cells (International Journal of Cancer 118 DOI:10.1002/ijc.21365);Ursodeoxycholic acid inhibits interleukin beta 1 and deoxycholic acid-induced activation of NF-κB and AP-1 in human colon cancer cells

International Journal of Cancer

Volumn 118, Issue 3, 2006, Pages 532-539

  Shah, Syed A ^a   Volkov, Yuri ^a   Arfin, Qamrul ^a   Abdel Latif, Mohamed M ^a   Kelleher, Dermot ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Activator protein 1; Colorectal cancer; Deoxycholic acid; Nuclear factor kappa B; Ursodeoxycholic acid

Indexed keywords

BISINDOLYLMALEIMIDE; CALPHOSTIN C; DEOXYCHOLIC ACID; DNA; ENHANCED GREEN FLUORESCENT PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELA; URSODEOXYCHOLIC ACID;

ARTICLE; CANCER CELL; CANCER PREVENTION; CELL NUCLEUS; CHEMOPROPHYLAXIS; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DRUG MECHANISM; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; PRIORITY JOURNAL; PROTEIN DNA BINDING; WESTERN BLOTTING;

EID: 30444446498     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21597     Document Type: Erratum

References (47)

1. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975;15:617-31.
2. Rafter J, Child P, Anderson AM, Alder R, Eng V, Bruce R. Cellular toxicity of faecal water depends on diet. Am J Nutr 1987;45:559-63.
3. Lapre JA, Van der Meer R. Diet-induced increase of colonic bile acids stimulates lytic activity of faecal water and proliferation of colonic cells. Carcinogenesis 1992;13:41-4.
4. Stadler J, Stern HS, Yeung KS, McGuire V, Furrer R, Marcon N, Bruce WR. Effect of high fat consumption on cell proliferation activity of colorectal mucosa and on soluble faecal bile acids. Gut 1988;29:1326-31.
5. Milovic V, Teller IC, Faust D, Caspary WF, Stein J. Effects of deoxycholate on human colon cancer cells: apoptosis or proliferation. Eur J Clin Invest 2002;1:29-34.
6. Reddy BS, Wynder EL. Metabolic epidemiology of colon cancer. Faecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer Res 1977;39:2533-9.
7. Bayerdorffer E, Mannes GA, Richter WO, Ochsenkuhn T, Wiebecke B, Kopeke W, Paumgartner G. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993;104:145-51.
8. Hori T, Matsumoto K, Sakaitani Y, Sato M, Morotomi M. Effect of dietary deoxycholic acid and cholesterol on faecal steroid concentration and its impact on the colonic crypt cell proliferation in azoxymethane-treated rats. Cancer Lett 1998;124:79-84.
9. Narisawa T, Magadia NE, Weisburger JH, Wynder EL. Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N′-nitro-N-nitrosoguanidine in rats. J Natl Cancer inst 1974;53:1093-7.
10. Wali RK, Frawley BP Jr, Hartmann S, Roy HK, Khare S, Scaglione-Sewell BA, Earnest DL, Sitrin MD, Brasitus TA, Bissonnette M. Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta. Cancer research 1995;55:5257-64.
11. Narisawa T, Fukaura Y, Takeba N, Nakai K. Chemoprevention of N-methylnitrosourea-induced colon carcinogenesis by ursodeoxycholic-5 aminosalicylic acid conjugate in F344 rats. Jpn Cancer Res 2002;93:143-50.
12. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
13. Ochsenkuhn T, Baydorffer E, Meining A, Schinkel M, Thiede C, Nussler V, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999;85:1664-9.
14. Venturi M, Hambly RJ, Glinghammer B, Rafter JJ, Rowland IR. Genotoxic activity in human faecal water and role of bile acids: a study using alkaline comet assay. Carcinogenesis 1997;18:2353-9.
15. Qiao D, Chen W, Stratagoules ED, Martinez JD. Bile acid-induced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase C signalling. J Biol Chem 2000;275:15090-8.
16. Huang XP, Fan XT, Desjeux M, Castagna M. Bile acids, non-phorbol-ester- type tumour promoters, stimulate the phosphorylation of protein kinase C substrates in human platelets and colon cell line HT 29. Int J Cancer 1992;52:444-50.
17. Glinghammer B, Inoue H, Rafter JJ. Deoxycholic acid causes DNA damage in colonic cells with subsequent induction of caspases, COX-2 promotor activity and the transcription factor NF-κB and AP-1. Carcinogenesis 2002;23:839-45.
18. Hirano F, Tanada H, Makino Y, Okamoto K, Hiramoto M, Handa H, Makino I. Induction of transcription factor AP-1 in cultured human colon adenocarcinoma cells following exposure to bile acids. Carcinogenesis 1996;17:427-3 3.
19. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
20. Miyamoto S, Verma IM. Rel/NF-κB/IκB story. Adv Cancer Res 1995;66:255-92.
21. Martin AG, San-Antonio B, Fresno M. Regulation of Nuclear Factor-κB Transactivation. Implication of phosphatidylinositol 3-kinase and protein kinase C zeta in c-Rel activation by tumour necrosis factor alpha. J Biol Chem 2001;276:15840-9.
22. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappa B. J Clin Invest 2001;107:241-6.
23. Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ, Baldwin AS Jr. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997;278:1812-5.
24. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002;64:883-8.
25. Lind D S, Hochwald S N, Malaty J, Rekkas S, Hebig P, Mishra G, Moldawer LL, Copeland EM, Mackay S. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 2001;130:363-9.
26. Gilmore TD, Koedood M, Piffat KA, White DW. Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene 1996;13:1367-78.
27. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in proliferation and transformation. Biochem Biophys Acta 1991;1072:129-57.
28. Nishizuka Y. The molecular heterogeneity of protein kinase c and its implications for cellular regulation. Nature 1988;334:661-5.
29. Yu HG, Yu LL, Yang Y, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F. Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology 2003;65:37-45.
30. Wang Q, Wang X, Evers BM. Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B. J Biol Chem 2003;278:51091-9.
31. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappa B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20:4188-97.
32. Cusack JC Jr. Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver. Ann Surg Oncol 2003;10:852-62.
33. Cusack CJ, Liu R, Heuston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic NF-κB inhibition. Cancer Res 2001;61:3535-40.
34. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40.
35. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 1999;274:27307-14.
36. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001;20:7597-609.
37. Suto R, Tominaga K, Mizuguchi H, Sasaki E, Higuchi K, Kim S, Iwao H, Arakawa T. Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer. Gene Ther 2004;11:187-93.
38. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-6.
39. Guo YS, Hellmich MR, Wen XD, Townsend CM Jr. Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells. J Biol Chem 2001;276:22941-7.
40. Li JJ, Westergaard C, Ghosh P, Colburn NH. Inhibitors of both nuclear factor-kappa B and activator protein-1 activation block the neoplastic transformation response. Cancer Res 1997;57:3569-76.
41. Joo SS, Won TJ, Lee do I. Potential role of ursodeoxycholic acid in suppression of nuclear factor kappa B in microglial cell line (BV-2). Arch Pharmacol Res 2004;27:954-60.
42. Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappa B p65/RelA subunit. Mol Cell Biol 1999;19:4798-805.
43. Hirano M, Hirai S, Mizuno K, Osada S, Hosaka M, Ohno S. A protein kinas C isoenzyme, nPKC epsilon is involved in the activation of NF-kappa B by 12-O-tetradecanoylphorbol-13-acetate (TPA) in rat 3Y1 fibroblasts. Biochem Biophys Res Commun 1995;206:429-36.
44. Im E, Martinez JD. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr 2004;134:483-6.
45. Momen MA, Monden Y, Houchi H, Umemot A. Effect of ursodeoxycholic acid on azoxymethane-induced aberrant crypt foci formation in rat colon: in vitro potential role of intracellular Ca2+. J Med Invest 2002;49:67-73.
46. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93.
47. Jacoby RF, Cole CE, Hawk ET, Lubet RA. Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 2004;127:838-44.